Previous 10 | Next 10 |
WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that it has completed the init...
New York City, NY:March 26, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Acinetobacter Infections Treatment Market in Global Industry: 2020 Research and New Innovations in Pharmaceuticals and Healthcare Sector. The prime objective of the r...
Gainers: USD Partners (NYSE: USDP ) +127% . More news on: USD Partners LP, Guess', Inc., Harvest Capital Credit Corp., Stocks on the move, , Read more ...
Entasis Therapeutics (NASDAQ: ETTX ): FY GAAP EPS of -$3.33 misses by $0.40 . More news on: Entasis Therapeutics Holdings Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
WALTHAM, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its full year 2019 financial results and business highlights. ...
Entasis Therapeutics (NASDAQ: ETTX ): Q3 GAAP EPS of -$0.27. Revenue of $7M Press Release More news on: Entasis Therapeutics, Earnings news and commentary, Healthcare stocks news, ,
WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its third quarter financial results for the period ended Septem...
WALTHAM, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant infections, today announced the appointment of David Altarac, M.D., MPA a...
WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Michael Gutch, Chief Business Officer and Chief ...
WALTHAM, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant infections, today announced its participation in an industry panel presen...
News, Short Squeeze, Breakout and More Instantly...
Entasis Therapeutics Holdings Inc. Company Name:
ETTX Stock Symbol:
NASDAQ Market:
Entasis Therapeutics Holdings Inc. Website:
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. , a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced ...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the s...
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society...